Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.

Abstract:

Importance:Esophageal adenocarcinoma and its precursor lesion Barrett esophagus have seen a dramatic increase in incidence over the past 4 decades yet marked genetic heterogeneity of this disease has precluded advances in understanding its pathogenesis and improving treatment. Objective:To identify novel disease susceptibility variants in a familial syndrome of esophageal adenocarcinoma and Barrett esophagus, termed familial Barrett esophagus, by using high-throughput sequencing in affected individuals from a large, multigenerational family. Design, Setting, and Participants:We performed whole exome sequencing (WES) from peripheral lymphocyte DNA on 4 distant relatives from our multiplex, multigenerational familial Barrett esophagus family to identify candidate disease susceptibility variants. Gene variants were filtered, verified, and segregation analysis performed to identify a single candidate variant. Gene expression analysis was done with both quantitative real-time polymerase chain reaction and in situ RNA hybridization. A 3-dimensional organotypic cell culture model of esophageal maturation was utilized to determine the phenotypic effects of our gene variant. We used electron microscopy on esophageal mucosa from an affected family member carrying the gene variant to assess ultrastructural changes. Main Outcomes and Measures:Identification of a novel, germline disease susceptibility variant in a previously uncharacterized gene. Results:A multiplex, multigenerational family with 14 members affected (3 members with esophageal adenocarcinoma and 11 with Barrett esophagus) was identified, and whole-exome sequencing identified a germline mutation (S631G) at a highly conserved serine residue in the uncharacterized gene VSIG10L that segregated in affected members. Transfection of S631G variant into a 3-dimensional organotypic culture model of normal esophageal squamous cells dramatically inhibited epithelial maturation compared with the wild-type. VSIG10L exhibited high expression in normal squamous esophagus with marked loss of expression in Barrett-associated lesions. Electron microscopy of squamous esophageal mucosa harboring the S631G variant revealed dilated intercellular spaces and reduced desmosomes. Conclusions and Relevance:This study presents VSIG10L as a candidate familial Barrett esophagus susceptibility gene, with a putative role in maintaining normal esophageal homeostasis. Further research assessing VSIG10L function may reveal pathways important for esophageal maturation and the pathogenesis of Barrett esophagus and esophageal adenocarcinoma.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Fecteau RE,Kong J,Kresak A,Brock W,Song Y,Fujioka H,Elston R,Willis JE,Lynch JP,Markowitz SD,Guda K,Chak A

doi

10.1001/jamaoncol.2016.2054

subject

Has Abstract

pub_date

2016-10-01 00:00:00

pages

1333-1339

issue

10

eissn

2374-2437

issn

2374-2445

pii

2537186

journal_volume

2

pub_type

杂志文章
  • Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

    abstract:IMPORTANCE:Substantial progress has been made in cancer diagnosis and treatment, resulting in a steady improvement in cancer survival. The degree of improvement by age, race, and sex remains unclear. OBJECTIVE:To quantify the degree of survival improvement over time by age, race, and sex in the United States. DESIGN,...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2014.161

    authors: Zeng C,Wen W,Morgans AK,Pao W,Shu XO,Zheng W

    更新日期:2015-04-01 00:00:00

  • Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

    abstract:IMPORTANCE:The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large data...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.1184

    authors: Larkin J,Lao CD,Urba WJ,McDermott DF,Horak C,Jiang J,Wolchok JD

    更新日期:2015-07-01 00:00:00

  • Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

    abstract:Importance:A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2295

    authors: Radovich M,Jiang G,Hancock BA,Chitambar C,Nanda R,Falkson C,Lynce FC,Gallagher C,Isaacs C,Blaya M,Paplomata E,Walling R,Daily K,Mahtani R,Thompson MA,Graham R,Cooper ME,Pavlick DC,Albacker LA,Gregg J,Solzak JP,C

    更新日期:2020-09-01 00:00:00

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

    abstract:Importance:Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown. Objectives:To i...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.3676

    authors: Ferrara R,Mezquita L,Texier M,Lahmar J,Audigier-Valette C,Tessonnier L,Mazieres J,Zalcman G,Brosseau S,Le Moulec S,Leroy L,Duchemann B,Lefebvre C,Veillon R,Westeel V,Koscielny S,Champiat S,Ferté C,Planchard D,Remon

    更新日期:2018-11-01 00:00:00

  • Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

    abstract:Importance:Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective:To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2016.3904

    authors: Melisko ME,Goldman ME,Hwang J,De Luca A,Fang S,Esserman LJ,Chien AJ,Park JW,Rugo HS

    更新日期:2017-03-01 00:00:00

  • Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

    abstract:Importance:To date, the benefit of genome-driven cancer therapy has not been quantified. Objective:We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven ther...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1660

    authors: Marquart J,Chen EY,Prasad V

    更新日期:2018-08-01 00:00:00

  • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

    abstract:Importance:The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. Objective:To compare 6 cycles of paclitaxel plus carboplatin (PCb) wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2965

    authors: Yu KD,Ye FG,He M,Fan L,Ma D,Mo M,Wu J,Liu GY,Di GH,Zeng XH,He PQ,Wu KJ,Hou YF,Wang J,Wang C,Zhuang ZG,Song CG,Lin XY,Toss A,Ricci F,Shen ZZ,Shao ZM

    更新日期:2020-09-01 00:00:00

  • Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.

    abstract:Importance:Breast cancer risk and comorbidities increase with age. Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer. Objective:To examine the association of chemotherapy with survival in elderly patients with mult...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2388

    authors: Tamirisa N,Lin H,Shen Y,Shaitelman SF,Sri Karuturi M,Giordano SH,Babiera G,Bedrosian I

    更新日期:2020-10-01 00:00:00

  • Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

    abstract:Importance:Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differenc...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.2993

    authors: Smeltzer MP,Faris NR,Ray MA,Osarogiagbon RU

    更新日期:2018-01-01 00:00:00

  • Time to Surgery and Breast Cancer Survival in the United States.

    abstract:IMPORTANCE:Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association. OBJECTIVE:To investigate the relationship between the time from diagnosis to breast cancer surgery and survival, usin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.4508

    authors: Bleicher RJ,Ruth K,Sigurdson ER,Beck JR,Ross E,Wong YN,Patel SA,Boraas M,Chang EI,Topham NS,Egleston BL

    更新日期:2016-03-01 00:00:00

  • BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

    abstract:IMPORTANCE:BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients. OBJECTIVES:To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use o...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.5941

    authors: Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S,Borges VF,Larsen B,Garber JE,Partridge AH

    更新日期:2016-06-01 00:00:00

  • Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.

    abstract:IMPORTANCE:Multiple myeloma has been classified as exhibiting "limited or suggestive evidence" of an association with exposure to herbicides in Vietnam War veterans. Occupational studies have shown that other pesticides (ie, insecticides, herbicides, fungicides) are associated with excess risk of multiple myeloma and i...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.2938

    authors: Landgren O,Shim YK,Michalek J,Costello R,Burton D,Ketchum N,Calvo KR,Caporaso N,Raveche E,Middleton D,Marti G,Vogt RF Jr

    更新日期:2015-11-01 00:00:00

  • Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

    abstract:Importance:RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may repres...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6065

    authors: Seligmann JF,Elliott F,Richman SD,Jacobs B,Hemmings G,Brown S,Barrett JH,Tejpar S,Quirke P,Seymour MT

    更新日期:2016-05-01 00:00:00

  • Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

    abstract:Importance:Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-cell therapy, was the first US Food and Drug Administration-approved, genetically engineered T-cell therapy for adults with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy. There has not ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2019.3869

    authors: Locke FL,Go WY,Neelapu SS

    更新日期:2020-02-01 00:00:00

  • Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

    abstract:Importance:Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associatio...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.3340

    authors: Gierach GL,Curtis RE,Pfeiffer RM,Mullooly M,Ntowe EA,Hoover RN,Nyante SJ,Feigelson HS,Glass AG,Berrington de Gonzalez A

    更新日期:2017-02-09 00:00:00

  • Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.

    abstract:Importance:Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have achieved success in treating a number of malignancies. However, only a subset of patients responds to these therapies, and optimization of patient sele...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.2214

    authors: Dijkstra KK,Voabil P,Schumacher TN,Voest EE

    更新日期:2016-11-01 00:00:00

  • Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

    abstract:Importance:A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. Objective:To describe clinical outcomes for women with a high RS who received adjuvant chemotherapy plus endo...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.4794

    authors: Sparano JA,Gray RJ,Makower DF,Albain KS,Saphner TJ,Badve SS,Wagner LI,Kaklamani VG,Keane MM,Gomez HL,Reddy PS,Goggins TF,Mayer IA,Toppmeyer DL,Brufsky AM,Goetz MP,Berenberg JL,Mahalcioiu C,Desbiens C,Hayes DF,Dees

    更新日期:2020-03-01 00:00:00

  • Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

    abstract:Importance:The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain. Objective:To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer....

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2016.1197

    authors: Powles T,Sarwar N,Stockdale A,Sarker SJ,Boleti E,Protheroe A,Jones R,Chowdhury S,Peters J,Oades G,O'Brien T,Sullivan M,Aitchison M,Beltran L,Worth D,Smith K,Michel C,Trevisan G,Harvey-Jones E,Wimalasingham A,Sahde

    更新日期:2016-10-01 00:00:00

  • Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

    abstract:Importance:Programmed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potentially life-threatening adverse event. Little is known about its incidence across different tumor types and treatment regimens. Objective:To compare the incidence of PD-1 inhibitor-related pneumonitis amon...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1001/jamaoncol.2016.2453

    authors: Nishino M,Giobbie-Hurder A,Hatabu H,Ramaiya NH,Hodi FS

    更新日期:2016-12-01 00:00:00

  • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

    abstract:Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this diseas...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.0219

    authors: Frezza AM,Jones RL,Lo Vullo S,Asano N,Lucibello F,Ben-Ami E,Ratan R,Teterycz P,Boye K,Brahmi M,Palmerini E,Fedenko A,Vincenzi B,Brunello A,Desar IME,Benjamin RS,Blay JY,Broto JM,Casali PG,Gelderblom H,Grignani G,

    更新日期:2018-09-01 00:00:00

  • Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study.

    abstract:IMPORTANCE:Contrary to practice guidelines, breast magnetic resonance imaging (MRI) is commonly used in the preoperative evaluation of women with breast cancer. While existing literature has found little benefit to MRI in most patients, potential downstream consequences associated with breast MRI are not well described...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3018

    authors: Arnaout A,Catley C,Booth CM,McInnes M,Graham I,Kumar V,Simos D,Van Walraven C,Clemons M

    更新日期:2015-12-01 00:00:00

  • Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.

    abstract:Importance:The evidence for concurrent chemoradiotherapy (CT-RT) in International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix is not robust. This study reports the final results of a randomized clinical trial of concurrent cisplatin-based CT-RT and radiotherap...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.5179

    authors: Shrivastava S,Mahantshetty U,Engineer R,Chopra S,Hawaldar R,Hande V,Kerkar RA,Maheshwari A,Shylasree TS,Ghosh J,Bajpai J,Gurram L,Gulia S,Gupta S,Gynecologic Disease Management Group.

    更新日期:2018-04-01 00:00:00

  • Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

    abstract:IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.6315

    authors: Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

    更新日期:2016-06-01 00:00:00

  • Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.

    abstract:IMPORTANCE:A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the low-dose arm (60 Gy) with concurrent chemotherapy. OBJE...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2015.3969

    authors: Movsas B,Hu C,Sloan J,Bradley J,Komaki R,Masters G,Kavadi V,Narayan S,Michalski J,Johnson DW,Koprowski C,Curran WJ Jr,Garces YI,Gaur R,Wynn RB,Schallenkamp J,Gelblum DY,MacRae RM,Paulus R,Choy H

    更新日期:2016-03-01 00:00:00

  • Resource Use and Medicare Costs During Lay Navigation for Geriatric Patients With Cancer.

    abstract:Importance:Lay navigators in the Patient Care Connect Program support patients with cancer from diagnosis through survivorship to end of life. They empower patients to engage in their health care and navigate them through the increasingly complex health care system. Navigation programs can improve access to care, enhan...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6307

    authors: Rocque GB,Pisu M,Jackson BE,Kvale EA,Demark-Wahnefried W,Martin MY,Meneses K,Li Y,Taylor RA,Acemgil A,Williams CP,Lisovicz N,Fouad M,Kenzik KM,Partridge EE,Patient Care Connect Group.

    更新日期:2017-06-01 00:00:00

  • Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.

    abstract:Importance:Novel intermediate end points may be useful to detect signals of early activity and prioritize new therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC). Objective:To explore milestone rate, a proposed intermediate end point for immunotherapy...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2017.1029

    authors: Blumenthal GM,Zhang L,Zhang H,Kazandjian D,Khozin S,Tang S,Goldberg K,Sridhara R,Keegan P,Pazdur R

    更新日期:2017-08-10 00:00:00

  • The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.

    abstract:IMPORTANCE:Although axillary lymph node evaluation is standard of care in the surgical management of invasive breast cancer, a benefit has not been demonstrated in ductal carcinoma in situ (DCIS). Despite uncertainty regarding the efficacy, axillary evaluation is often performed in women with DCIS. OBJECTIVE:To determ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.0389

    authors: Coromilas EJ,Wright JD,Huang Y,Feldman S,Neugut AI,Chen L,Hershman DL

    更新日期:2015-06-01 00:00:00

  • Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women.

    abstract:Importance:Colorectal cancer (CRC) incidence and mortality among individuals younger than 50 years (early-onset CRC) are increasing. The reasons for such increases are largely unknown, although the increasing prevalence of obesity may be partially responsible. Objective:To investigate prospectively the association bet...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.4280

    authors: Liu PH,Wu K,Ng K,Zauber AG,Nguyen LH,Song M,He X,Fuchs CS,Ogino S,Willett WC,Chan AT,Giovannucci EL,Cao Y

    更新日期:2019-01-01 00:00:00

  • Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

    abstract:Importance:The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and s...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.3361

    authors: Slovin S,Clark W,Carles J,Krivoshik A,Park JW,Wang F,George D

    更新日期:2018-05-01 00:00:00

  • The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.

    abstract:Importance:For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and several immune checkpoint blockers (ICBs) that have been added to the t...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3381

    authors: Pinter M,Jain RK,Duda DG

    更新日期:2021-01-01 00:00:00